Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Equity Average (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Equity Average for 4 consecutive years, with $233.0 million as the latest value for Q4 2025.

  • Quarterly Equity Average rose 190.62% to $233.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $233.0 million through Dec 2025, up 190.62% year-over-year, with the annual reading at $159.2 million for FY2025, 117.44% up from the prior year.
  • Equity Average hit $233.0 million in Q4 2025 for Taysha Gene Therapies, roughly flat from $233.9 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $233.9 million in Q3 2025 to a low of -$43.1 million in Q3 2023.
  • Historically, Equity Average has averaged $67.5 million across 4 years, with a median of $63.3 million in 2025.
  • Biggest five-year swings in Equity Average: plummeted 299.56% in 2023 and later surged 1019.97% in 2024.
  • Year by year, Equity Average stood at $5.8 million in 2022, then surged by 121.62% to $12.9 million in 2023, then soared by 520.85% to $80.2 million in 2024, then soared by 190.62% to $233.0 million in 2025.
  • Business Quant data shows Equity Average for TSHA at $233.0 million in Q4 2025, $233.9 million in Q3 2025, and $151.9 million in Q2 2025.